• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma.

作者信息

Lythgoe Hanna, Baildam Eileen, Beresford Michael W, Cleary Gavin, McCann Liza J, Pain Clare E

机构信息

Department of Paediatric Rheumatology, Liverpool, UK.

NIHR Alder Hey Clinical Research Facility, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

出版信息

Rheumatology (Oxford). 2018 Feb 1;57(2):398-401. doi: 10.1093/rheumatology/kex382.

DOI:10.1093/rheumatology/kex382
PMID:29077971
Abstract
摘要

相似文献

1
Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma.托珠单抗作为重度难治性儿童局限性硬皮病的一种潜在治疗选择。
Rheumatology (Oxford). 2018 Feb 1;57(2):398-401. doi: 10.1093/rheumatology/kex382.
2
Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial.甲氨蝶呤治疗儿童局限性硬皮病：一项随机、双盲、安慰剂对照试验。
Arthritis Rheum. 2011 Jul;63(7):1998-2006. doi: 10.1002/art.30264.
3
A Case of Pansclerotic Morphea Treated With Tocilizumab.一例用托珠单抗治疗的泛硬化性硬斑病病例。
JAMA Dermatol. 2019 Mar 1;155(3):388-389. doi: 10.1001/jamadermatol.2018.5040.
4
Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?托珠单抗治疗两名泛硬化性硬斑病患儿：对难治性病例是一种有希望的疗法吗？
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):211-213. Epub 2017 Sep 29.
5
Good response of linear scleroderma in a child to ciclosporin.一名儿童线性硬皮病对环孢素治疗反应良好。
Br J Dermatol. 2004 Apr;150(4):790-2. doi: 10.1111/j.0007-0963.2004.05901.x.
6
Clinical Profile of Methotrexate-resistant Juvenile Localised Scleroderma.甲氨蝶呤耐药性幼年局限性硬皮病的临床特征。
Acta Derm Venereol. 2019 May 1;99(6):539-543. doi: 10.2340/00015555-3155.
7
Effectiveness of topical calcitriol for localized scleroderma.外用骨化三醇治疗局限性硬皮病的疗效
J Rheumatol. 1999 Jan;26(1):239-40.
8
Treatment of systemic sclerosis with tocilizumab.用托珠单抗治疗系统性硬化症。
Rheumatology (Oxford). 2015 Feb;54(2):371-2. doi: 10.1093/rheumatology/keu435. Epub 2014 Dec 5.
9
Progressive hemifacial atrophy with linear scleroderma.进行性半侧面部萎缩伴线状硬皮病。
Pediatr Dermatol. 2005 Sep-Oct;22(5):436-9. doi: 10.1111/j.1525-1470.2005.00111.x.
10
Tocilizumab for refractory post-COVID-19 pansclerotic morphea.托珠单抗治疗难治性新冠后全硬化性硬斑病
J Eur Acad Dermatol Venereol. 2024 May;38(5):e364-e365. doi: 10.1111/jdv.19692. Epub 2023 Dec 11.

引用本文的文献

1
Janus kinase inhibitors in localized scleroderma: a systematic literature review.局部性硬皮病中的Janus激酶抑制剂：一项系统文献综述
Turk J Med Sci. 2025 Jun 7;55(3):533-539. doi: 10.55730/1300-0144.6000. eCollection 2025.
2
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review.青少年硬皮病的新型挑战性全身治疗方法：综述
Pharmaceuticals (Basel). 2025 Apr 28;18(5):643. doi: 10.3390/ph18050643.
3
What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.局限性硬皮病的新进展——分子层面及新靶向治疗的叙述性综述
J Clin Med. 2024 Nov 25;13(23):7134. doi: 10.3390/jcm13237134.
4
National Registry for Childhood Onset Scleroderma I: Insights from the first 341 juvenile localized scleroderma patients.全国儿童期起病硬皮病登记处I：来自首批341例青少年局限性硬皮病患者的见解。
J Scleroderma Relat Disord. 2024 Sep 23:23971983241272460. doi: 10.1177/23971983241272460.
5
Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma.干扰素-γ诱导蛋白-10（IP-10）和肿瘤坏死因子-α（TNF-α）作为局限性硬皮病活动疾病状态的血清学预测指标。
Int J Mol Sci. 2024 Sep 21;25(18):10134. doi: 10.3390/ijms251810134.
6
Recent Advances in Treatment of Systemic Sclerosis and Morphea.系统性硬皮病和硬斑病治疗的最新进展。
Am J Clin Dermatol. 2024 Mar;25(2):213-226. doi: 10.1007/s40257-023-00831-2. Epub 2023 Dec 12.
7
Morphea: The 2023 update.硬斑病：2023年更新版
Front Med (Lausanne). 2023 Feb 13;10:1108623. doi: 10.3389/fmed.2023.1108623. eCollection 2023.
8
Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy.接受免疫治疗的癌症患者中与免疫相关的罕见不良事件
Diagnostics (Basel). 2022 Aug 29;12(9):2091. doi: 10.3390/diagnostics12092091.
9
Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.霉酚酸酯治疗甲氨蝶呤耐药的儿童局限性硬皮病。
Rheumatology (Oxford). 2021 Mar 2;60(3):1387-1391. doi: 10.1093/rheumatology/keaa392.
10
Is biological therapy in systemic sclerosis the answer?生物疗法是系统性硬化症的答案吗？
Rheumatol Int. 2020 May;40(5):679-694. doi: 10.1007/s00296-020-04515-6. Epub 2020 Jan 20.